1-1 of 1
Daniel Leibovitz
Close
Sort by
Journal Articles

A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

Thomas S. Larsen, Oliver Manzke, Daniel Leibovitz, Michael Arbushites
Journal: Blood
Blood (2022) 140 (Supplement 1): 12077–12078.
https://doi.org/10.1182/blood-2022-160319
Published: 2022